FDA hands down $300M analytics BPA to Booz Allen, Octo
By
Ross Wilkers
The Food and Drug Administration awards Booz Allen Hamilton and Octo Consulting Group a seven-year, $300 million blanket purchase agreement for analytics-related services.
The Food and Drug Administration has awarded Booz Allen Hamilton and Octo Consulting Group a seven-year, $300 million blanket purchase agreement to help the agency further develop its drug resource management system.
The FDA is seeking to update its analytics platform used for the regulation, surveillance, compliance and enforcement oversight of drugs and medical devices.
Octo said in a release Tuesday the effort seeks to fulfill requirements from the 21st Century Care Act that mandates a more streamlined and efficient drug and device approval process.
In particular, the FDA wants to extend its drug evaluation processes that include human data submissions. The IT and services components include application lifecycle development, operations and maintenance and training.
Six offers were submitted for the BPA that was awarded via the General Services Administration’s IT Schedule 70 vehicle, according to Federal Procurement Spending Data information. The BPA’s ordering period ends on Oct. 31, 2024.